Sunan Cui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sunan Cui has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Jie Fu
University of California Los Angeles Department of Radiation Oncology, Los Angeles, California, 90095-6951, UNITED STATES
14 shared publications - Stephen R. Bowen
University of Washington
14 shared publications - Christina S. Baik
Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Fred Hutchinson Cancer Center, Seattle, Washington
13 shared publications - Clemens Grassberger
University of Washington 4 Seattle
13 shared publications - Daniel Scott Hippe
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA
13 shared publications - Faisal Yaseen
University of Washington
13 shared publications
Latest Publications
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Predictive variables considered in competing risk analysis for LRP/DM
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Predictive variables considered in competing risk analysis for LRP/DM
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Representativeness of Study Participants
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Representativeness of Study Participants
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Kaplan–Meier curves for OS (left column) and PFS (right column), stratified by PET response status (non-responder vs responder), treatment modality (proton vs photon), durvalumab use (durvalumab vs no durvalumab), histology (adenocarcinoma vs squamous cell carcinoma and other), and chemotherapy regimen (carboplatin + paclitaxel vs other).
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Kaplan–Meier curves for OS (left column) and PFS (right column), stratified by PET response status (non-responder vs responder), treatment modality (proton vs photon), durvalumab use (durvalumab vs no durvalumab), histology (adenocarcinoma vs squamous cell carcinoma and other), and chemotherapy regimen (carboplatin + paclitaxel vs other).
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Pattern of failures including death, LRP and DM
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Pattern of failures including death, LRP and DM
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Correlation among top features with DM in the cohort of PET non-responders.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Correlation among top features with DM in the cohort of PET non-responders.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate Fine-Gray-regression for LRP prediction: predictive variables with p values. All HR for continuous variables reported are based on a 1-standard deviation (SD) increase.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate Fine-Gray-regression for LRP prediction: predictive variables with p values. All HR for continuous variables reported are based on a 1-standard deviation (SD) increase.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
(A) Time-Dependent AUC with 95% confidence interval for DM predicted by mid.TLG at 0.5-years intervals across multiple time points. (B) Time-Dependent ROC Curve at 2 Years achieving AUC of 0.655, with no optimal threshold in TLG that maximized the Youden index.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
(A) Time-Dependent AUC with 95% confidence interval for DM predicted by mid.TLG at 0.5-years intervals across multiple time points. (B) Time-Dependent ROC Curve at 2 Years achieving AUC of 0.655, with no optimal threshold in TLG that maximized the Youden index.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate Fine-Gray Regression for DM prediction: predictive variables and p values. All HR for continuous variables reported are based on a 1-standard deviation (SD) increase.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate Fine-Gray Regression for DM prediction: predictive variables and p values. All HR for continuous variables reported are based on a 1-standard deviation (SD) increase.
- Open Access
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate analysis for DM in PET non-responders who had boost plans.
- 14 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-Guided and Risk-Adaptive Chemoradiation for Unresectable NSCLC
Univariate analysis for DM in PET non-responders who had boost plans.